Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 9-16

  Chappell, Jill C ^a   Eisenhofer, Graeme ^b,c   Owens, Michael J ^d   Haber, Harry ^e   Lachno, D Richard ^a   Dean, Robert A ^a   Knadler, Mary Pat ^a   Nemeroff, Charles B ^f   Mitchell, Malcolm I ^a   Detke, Michael J ^g,h   Iyengar, Smriti ^a   Pangallo, Beth ^a   Lobo, Evelyn D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Inst of Clinical Chemistry and Laboratory Medicine   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MMS HOLDINGS INC   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g Detke Biopharma   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HIAA; CSF; DHPG; Duloxetine; Norepinephrine; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DULOXETINE; ESCITALOPRAM; MIANSERIN; NORADRENALIN; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; CELL LINE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; EX VIVO STUDY; FEMALE; HUMAN; IN VIVO STUDY; MALE; MIDDLE AGED; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; CALIFORNIA; CENTRAL NERVOUS SYSTEM; CITALOPRAM; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TEXAS; THIOPHENES; YOUNG ADULT;

EID: 84891738871     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000061     Document Type: Article

References (40)

1. Fuller RW, Hemrick-Luecke SK, Snoddy HD. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther. 1994;269:132-136.
2. Engleman EA, Perry KW, Mayle DA, et al. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 1995;12:287-295.
3. Kihara T, Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther. 1995;272:177-183.
4. Kasamo K, Blier P, De MC. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther. 1996;277:278-286.
5. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25: 871-880.
6. Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55:320-322.
7. Wong DT. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Expert Opin Investig Drugs. 1998;7:1691-1699.
8. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11:1475-1493.
9. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl). 2006;185:395-399.
10. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatr Neurosci. 2007;32:86-102.
11. Turcotte JE, Debonnel G, De MC, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-521.
12. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28:1685-1693.
13. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
14. Trivedi MH, Desaiah D, Ossanna MJ, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008;23:161-169.
15. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63:424-434.
16. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227.
17. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219-245.
18. Goddard AW, Ball SG, Martinez J, et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety. 2010;27:339-350.
19. Mease PJ, Russell IJ, Kajdasz DK, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010;39:454-464.
20. Omiya Y, Yuzurihara M, Suzuki Y, et al. Role of alpha2-adrenoceptors in enhancement of antinociceptive effect in diabetic mice. Eur J Pharmacol. 2008;592:62-66.
21. Thor KB, KirbyM, Viktrup L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract. 2007;61:1349-1355.
22. Vincent S, Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004;109:3202-3207.
23. Goldstein DS, Eisenhofer G, Stull R, et al. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220.
24. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001;91:35-62.
25. Chappell JC, Kovacs R, Haber H, et al. Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: a mechanistic study using heart rate variability as a pharmacodynamic measure. J Clin Psychopharmacol. 2013;33:236-239.
26. Owens MJ, Krulewicz S, Simon JS, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33:3201-3212.
27. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159:1702-1710.
28. Davidson J, Watkins L, Owens M, et al. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol. 2005;25:480-484.
29. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345-350.
30. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142-1150.
31. Eisenhofer G, Goldstein DS, Stull R, et al. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem. 1986;32:2030-2033.
32. Lobo ED, Quinlan T, O'Brien L, et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet. 2009;48:189-197.
33. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843-1849.
34. Meyer JH,Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835.
35. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45:935-944.
36. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8:23-33.
37. Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci. 2009;14:5291-5338.
38. Kalk NJ, Nutt DJ, Lingford-Hughes AR. The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol. 2011;25:3-16.
39. Eisenhofer G. Sympathetic nerve functionVassessment by radioisotope dilution analysis. Clin Auton Res. 2005;15:264-283.
40. Baumert M, Lambert GW, Dawood T, et al. Short-term heart rate variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol. 2009;297:H674-H679.